
Estrogen receptor-positive (ER+) breast cancers are among the most common and treatable forms of the disease. Many patients respond well to a combination of endocrine therapy and CDK4/6 inhibitors—drugs like ribociclib that block the cell cycle and prevent tumor growth. But for up to half of these patients, treatment eventually fails. The tumor adapts and continues to grow, presenting a major barrier to developing more effective, long-term cancer therapies.
Continue reading “The Hidden Role of the Immune Microenvironment in ER+ Breast Cancer Resistance”